Background
Hypertension is an important risk factor for development of cardiovascular disease (CVD) and chronic kidney disease (CKD) [1] [2] [3] . According to previous estimates, the National Health and Nutrition Examination Survey (2005) (2006) (2007) (2008) showed that 98 million (21%) Americans have hypertension (defined as blood pressure [BP] >140/90 mm Hg). According to new estimates, an additional 52 million (11%) of American adults (for a total of 150 million adults [32%]) have uncontrolled BP requiring treatment (as defined by the American Heart Association Task Force as BP >140/90 mm Hg for lowrisk individuals; >130/80 mm Hg for Framingham risk score >10%, CKD, diabetes, and CVD; and >120/80 for congestive heart failure). Adults with diabetes (50.6 million), CKD (43.7 million), and CVD (43.3 million) have the greatest prevalence of uncontrolled BP [4] . Hypertension is present in nearly 75% of patients with CVD, including coronary artery disease, stroke, diabetes, CKD, and peripheral artery disease [5] [6] [7] ; however, it is estimated that only 53% of patients receiving antihypertensive treatment achieve BP control [7] . By 2030, it is estimated that 40.5% of the US population will have CVD [8] .
The prevalence of hypertension is disproportionately high in patients who have diabetes [9] , and individuals who have hypertension are nearly 2.5 times more likely to develop diabetes within 6 years than those without hypertension. Elevated BP is an important modifiable risk factor in patients with CKD, and BP reduction has the potential to both reduce cardiovascular death and attenuate progression of kidney disease [10] [11] [12] . It is estimated that triplecombination therapy is needed in at least 25% of all patients with hypertension in order to control BP [13] . Individuals who have hypertension and diabetes, CKD, or CVD are likely to need multiple antihypertensive agents to achieve the lower BP goals recommended in these high-risk populations [5, 6] . Furthermore, single-pill combination therapy may result in increased adherence through reduction in pill burden and simplification of the therapeutic regimen [14] . A study including~85,000 patients from Kaiser Permanente found that adherence decreased when the number of medications prescribed increased. In this study, antihypertensive medication adherence levels were 77.2%, 69.7%, 62.9%, and 55.5% in patients who received 1-, 2-, 3-, or 4-drug regimens, respectively [15] .
The triple combination of olmesartan medoxomil (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg resulted in statistically significantly greater reductions in seated diastolic BP (SeDBP) and seated systolic BP (SeSBP) than the component dualcombination treatments in the Triple Therapy with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in Hypertensive Patients Study (TRINITY) [16] . During the 40-week open-label extension period of the TRINITY study, continued administration of OM/AML/HCTZ triplecombination regimens demonstrated maintenance of the BP-lowering effects observed in the double-blind period of the study [17] . Furthermore, in the Blood Pressure Control in All Subgroups with Hypertension (BP-CRUSH) study (N=999), the addition of HCTZ to a single-pill combination of AML/OM allowed more patients to achieve SeBP goals [18] .
The objective of these subgroup analyses was to compare the triple-combination treatment of OM 40/AML 10/HCTZ 25 mg with the component dual-combination treatments (OM 40/AML 10 mg, OM 40/HCTZ 25 mg, and AML 10/ HCTZ 25 mg) in participants from the TRINITY study who had hypertension and diabetes (prespecified analysis) [19] , CKD (prespecified analysis), or chronic CVD (post hoc analysis), and to evaluate the long-term efficacy and safety of OM/AML/HCTZ in these high-risk subgroups.
Methods

Study population
Individuals in the TRINITY study (NCT00649389; http:// clinicaltrials.gov/ct2/show/NCT00649389) were aged ≥18 years with a mean SeBP ≥140/100 or ≥160/90 mm Hg (off antihypertensive medication) [16] . Persons with type 1 or type 2 diabetes controlled on a stable regimen with diet, insulin, or oral antidiabetes medications for ≥30 days and persons with CKD (creatinine clearance ≥30 mL/min and ≤60 mL/min) were eligible for inclusion. Persons with left ventricular hypertrophy, stable angina, peripheral vascular disease, and hypertensive retinopathy were also eligible for inclusion. Exclusion criteria included uncontrolled diabetes (with or without treatment) (ie, HbA1c >9.0%), stage IV CKD (ie, estimated glomerular filtration rate <30 mL/min/ 1.73 m 2 ), history of a recent stroke or transient ischemic attack, myocardial infarction, percutaneous coronary intervention, coronary artery bypass surgery, and/or unstable angina within 6 months of enrollment or New York Heart Association class III or IV congestive heart failure. Persons with secondary hypertension, symptomatic resting bradycardia, heart block greater than first-degree atrioventricular block, and chronic atrial fibrillation or flutter were also excluded. The study was conducted in accordance with the institutional review board committee regulations and the Declaration of Helsinki [20] . All patients provided written informed consent at screening, before undergoing any study procedures.
Study design
TRINITY was a phase 3, randomized, parallel-group study conducted at 317 clinical sites in the United States and Puerto Rico and consisted of a 12-week double-blind treatment period followed by a 40-week open-label treatment period. Details of the 12-week study design have been published previously [16] ; the study design for the 12-week double-blind and open-label treatment periods is summarized in Figure 1 . Eligible study participants (stratified by age, race, and diabetes status) were randomized to a regimen that resulted in the 4 [17] .
Study outcomes
The primary efficacy end point of the subgroup analyses was the least squares (LS) mean reduction from baseline in SeDBP at week 12 (primary efficacy registration requirement for OM/AML/HCTZ 
Statistical analysis
The primary efficacy analysis population was defined as all participants who received at least 1 dose of study medication and had assessments for SeDBP at baseline and at least once post dose. The safety population (for AE assessment) included all participants receiving at least 1 dose of study medication at or beyond the week 4 visit of the 12-week double-blind period. For the double-blind treatment period, two-sided P values for testing the significance of the triplecombination treatment versus each dual-combination treatment were derived from an analysis of covariance (ANCOVA) model that had baseline BP as a covariate and fixed effects of final randomized treatment, subgroup (eg, diabetes status subgroup), and final randomized treatment by subgroup interaction. For each comparison, the LS mean difference, corresponding standard error (SE), and two-sided P values were derived from the model. The proportion of participants reaching BP goal in each treatment group was summarized and analyzed using the chi square test. Comparisons between triple-combination treatment and each dualcombination treatment were performed using Fisher's exact test at a 0.05 significance level. The last observation carried forward (LOCF) approach was used for ET measurements during double-blind treatment. Summary statistics by dosing regimen were used to describe SeDBP and SeSBP at each open-label visit week and the proportion of participants reaching BP goal.
Results
Study participant disposition
A total of 2492 participants were randomized into the study, of whom 2116 completed the 12-week doubleblind treatment period, 2112 entered the 40-week openlabel extension period (4 participants completed the double-blind period of the study, but did not continue in the open-label period: 2 individuals withdrew consent and 2 individuals discontinued from the study due to AEs), and 1796 completed the study (Figure 2 ). Of the randomized participants, 387 (15.5%) had diabetes, 103 (4.1%) had CKD, and 227 (9.1%) had chronic CVD. Participants with comorbid diabetes, CKD, and/or CVD were included in each applicable subgroup. Baseline characteristics of these subgroups are summarized by treatment arm in Table 1 . For the diabetes, CKD, and chronic CVD subgroups, mean age was 58.7, 70.1, and 59.6 years and baseline BP was 171.7/98.5, 173.3/96.6, and 173.0/100.4 mm Hg, respectively.
Efficacy
Week 12
In study participants with diabetes, CKD, and chronic CVD, triple-combination treatment with OM 40/AML 10/HCTZ 25 mg resulted in greater BP reductions and a greater proportion of participants achieving BP goal of <130/80 mm Hg at week 12 (LOCF) compared with the dual-combination treatments ( Figure 3A , 3B and 3C). Mean SeBP at week 12 was 131.8/77.3, 127.0/72.9, and 132.3/79.9 mm Hg for participants with diabetes, CKD, and chronic CVD, respectively. The proportion of participants receiving triple-combination treatment who reached BP goal in each of these subgroups was 41.1% (diabetes), 55.0% (CKD), and 38.9% (chronic CVD).
Week 52
Mean BP and proportion of participants reaching BP goal (<130/80 mm Hg) during the open-label extension period in the diabetes, CKD, and chronic CVD subgroups is summarized in Table 2 . In the diabetes, CKD, and chronic CVD subgroups, mean SeBP at week 52/ET ranged from 121.4-136.7/74.9-79.7, 118.4-134.0/70.9-75.0, and 127.1-138.4/77.1-82.3 mm Hg, respectively. BP goal was reached by an average of 44.3%, 51.7%, and 33.7% of participants with diabetes, CKD, and chronic CVD, respectively.
Safety
No new safety concerns were identified for either the triple-or dual-combination treatments that were not known to occur with the individual component therapies.
Treatment-emergent AEs (TEAEs) for the diabetes, CKD, and chronic CVD subgroups during the double-blind treatment period are summarized in Table 3 . At week 12, 205 (56.3%), 56 (57.7%), and 119 (57.8%) study participants with diabetes, CKD, and chronic CVD, respectively, had a TEAE. Across all treatment groups for each subgroup, most TEAEs were considered mild or moderate in severity. In total, 11 (3.0%), 3 (3.1%), and 6 (2.9%) participants with diabetes, CKD, and chronic CVD had a serious AE (SAE) and 11 (3.0%), 3 (3.1%), and 6 (2.9%) discontinued from the study due to a TEAE.
The safety profile for these 3 subgroups during the openlabel treatment period is summarized in Table 4 . The most common TEAEs (≥5%) across doses during the open-label extension period were upper respiratory tract infection (11; 5.4%) in participants with diabetes; dizziness (3; 9.4%), nasopharyngitis (3; 7.7%), and urinary tract infection (3; 7.7%) in participants with CKD; and dizziness (6; 6.3%) and cough (5; 5.3%) in participants with chronic CVD.
Although small changes were observed in serum chemistry and hematology parameters, there was no apparent relationship to the dose or combination of therapy, and none were considered clinically significant. For the total cohort at week 12/ET, mean glucose levels (non-fasted) were 113.6 mg/dL (baseline: 108. for the respective treatment groups. No effects on heart rate, electrocardiograms, or physical examinations were observed during the treatment period of the study.
Discussion
The current subgroup analyses demonstrated the effectiveness of triple-combination treatment in difficultto-treat participants with hypertension and diabetes, CKD, or chronic CVD. BP reductions with triple-combination treatment in these subgroups at week 12 were comparable to those for the overall study cohort (−37/22 mm Hg) [16] . Long-term treatment with varying doses of OM/ AML/HCTZ in these subgroups resulted in similar BP-lowering effects for those receiving triple-combination treatment during the double-blind period of the study. Triple-combination treatment also enabled these high-risk subgroups to achieve BP goal (<130/80 mm Hg) at week 12 and at week 52. Triple-combination treatment was well tolerated in these subgroups, with a low percentage of participants discontinuing treatment across treatment groups and no clinically meaningful differences in AEs. The presence of diabetes, CKD, or chronic CVD did not change the AE profile of the drugs used in this analysis from that observed in the total TRINITY study cohort [16] .
It has been estimated that at least 75% of patients with hypertension require combination therapy to maintain BP control [14] , and large clinical trials have reported that 23-54% of participants require 3 or more antihypertensive agents [21] [22] [23] [24] . Thus, there is a growing emphasis on the need for practical strategies to consistently achieve and maintain BP goals with the use of multiple antihypertensive agents in clinical practice [14] .
Single-pill combination therapy may improve BP control through regimen simplification, which may lead to an improvement in patient adherence, reduction in physician visits, and attainment of BP goals [14, 16, [25] [26] [27] [28] [29] [30] . Single-pill combinations have the potential to increase adherence to therapy compared with free-dose combinations [31, 32] , particularly in patients with hypertension and cardiovascular comorbidities. Such patients are at increased risk of nonadherence due to the need for multiple medications (See figure on previous page.) Figure 3 Diabetes (A), CKD (B), and chronic CVD (C) subgroups: LS Mean (SE) reductions in SeBP and proportion of participants reaching BP goal (<130/80 mm Hg) at week 12 (LOCF). Specific P values are found beneath each panel. AML, amlodipine besylate; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; HCTZ, hydrochlorothiazide; LOCF, last observation carried forward; LS, least squares; OM, olmesartan medoxomil; SE, standard error. † Drug-related was defined as definitely, probably, or possibly related to randomized study medication. ‡ TEAEs presented occurred in >5% and at least 3 study participants in any treatment group. AE, adverse event; AML, amlodipine besylate; CVD, cardiovascular disease; CKD, chronic kidney disease; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; TEAE, treatment-emergent adverse event. for a variety of comorbidities (eg, dyslipidemia, diabetes) in addition to antihypertensive medications [33, 34] . Combining antihypertensive agents from different classes has been estimated to produce BP reductions approximately 5 times greater than doubling the dose of any single agent [35] . A meta-analysis has shown that one drug at standard dose compared with a combination of 3 drugs at half the standard dose reduced the incidence of coronary heart disease by about 24% and 45%, respectively, and stroke by 33% and 60%, respectively, in individuals aged 60 to 69 years with SeBP of 150/90 mm Hg [36] . The complementary mechanisms of action of an angiotensin receptor blocker, calcium channel blocker, and diuretic result in each agent targeting a separate pathway and provide coverage for multiple different pathways contributing to hypertension [14, 25, 35] . Additionally, in patients with evidence of renal disease or at greater risk of developing renal disease, such as those with diabetes mellitus, it is recommended to use reninangiotensin-aldosterone system blocker-based combination therapy [37, 38] .
Guidelines recognize that multiple antihypertensive agents are often required in patients with diabetes and CKD [5] . In addition, the American Heart Association recommends starting with ≥2 antihypertensive agents in patients with coronary artery disease [6] . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends a lower BP goal (<130/80 mm Hg) for patients with diabetes or CKD, as both are major risk factors for CVD [5] . Similarly, the American Heart Association/American College of Cardiology recommends a BP goal of <130/80 mm Hg for patients at high risk for or with demonstrated coronary artery disease [6] . The American College of Cardiology Foundation/American Heart Association/American Medical AssociationPhysician Consortium for Performance Improvement 2011 Performance Measures for Adults with Coronary Artery Disease and Hypertension report also states that lower BP targets may be appropriate for some patients with coronary artery disease [39] .
Despite the evidence supporting the benefit of targeted BP control in high-risk patient groups, some investigators have raised questions regarding incremental benefit with more aggressive BP goals [40] [41] [42] . The European Society of Hypertension guidelines note that many recommendations on hypertension management are based on post hoc analyses rather than prospective randomized trial data, with the latter being a preferable evidence base for BP target recommendations in different patient groups [43] . At present, it appears reasonable to adhere to currently established guideline targets and goals of <130/80 mm Hg in these high-risk patient groups.
Limitations to the current subgroup and post hoc analyses include that statistical analyses between the subgroups were not completed because of the unequal participant numbers in the subgroups. In addition, the TRINITY study only evaluated the highest doses of each of the 3 agents in the dual-and triple-combination regimens; therefore, it does not provide information on the efficacy and safety of the lower dosing regimens. This study also excluded individuals with illnesses such as symptomatic heart failure and therefore it cannot be determined whether the triple-combination treatment is appropriate for this patient population; caution must be exercised regarding generalizability of these data to the overall population.
Conclusions
Treatment with OM 40/AML 10/HCTZ 25 mg resulted in greater reductions in SeBP compared with each dualcombination treatment in high-risk subgroups of participants (diabetes, CKD or chronic CVD) from the TRIN-ITY study. Also, a greater proportion of participants in each subgroup achieved BP goal (<130/80 mm Hg) with the triple combination at week 12 compared with the dual-combination treatments, which was maintained during the open-label period of the study. Long-term triple-combination therapy was well tolerated.
